Portfolio

Opiant Pharmaceuticals secures $50m in convertible debt financing

By 10/12/2020June 4th, 2021No Comments

Opiant Pharmaceuticals Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security Agreement (“Agreement”) with a syndicate of Pontifax Medison Finance (“Pontifax”), a healthcare-dedicated venture and debt fund, and Kreos Capital, Europe’s leading growth debt firm.

Opiant plans to use the proceeds to fund the potential future commercialization of OPNT003, nasal nalmefene, an investigational treatment for opioid overdose, which the company aims to file for approval by the U.S. Food and Drug Administration (“FDA”) at the end of 2021.

Under the Agreement, Opiant will be able to draw up to $50 million in three tranches. The first tranche of $20 million was funded at closing on December 10, 2020; a second tranche of $10 million will be available upon submission of a New Drug Application to the FDA; and a third tranche of $20 million will be funded upon FDA approval of an opioid overdose product. Each tranche will mature over 5 years and have an interest-only period of 30 months at an average rate of 8.75%. Subject to certain limitations, Pontifax and Kreos can elect to convert up to half of their outstanding loan into shares of Opiant’s common stock at a conversion price of $19.64 per share. Further information with respect to the Agreement is set forth in a Form 8-K filed by Opiant with the Securities and Exchange Commission on December 10, 2020.

“This financing, together with the $31.1 million of cash on our balance sheet, provides Opiant with the financial flexibility to potentially launch OPNT003 without the need for additional financing,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “This Agreement, along with the recent appointment of Craig Collard, a seasoned biopharma leader, as Chairman of our Board of Directors, positions us well to deliver on our mission to develop and bring to market best-in-class medicines for addiction and overdose.”

“We look forward to partnering with a company as innovative as Opiant,” said Momi Karako, partner at Pontifax. “The Company is making excellent progress advancing OPNT003, and it is a privilege to be working with a team whose potential to make a difference is so great.”

“Kreos is pleased to provide this financing to Opiant,” said Aris Constantinides, partner at Kreos Capital. “This is an underserved market and Opiant, a company advancing the field of addiction, could play an important role in addressing the growing opioid addiction crisis.”

Jefferies acted as the exclusive financial adviser to Opiant and Wilson, Sonsini, Goodrich & Rosati served as legal advisor. Kramer Levin acted as legal advisor to Pontifax and Kreos Capital.